FdaApplication
BLA 020563
Identifiers
- fda_app_no: BLA020563
Properties
| Property | Value |
|---|---|
| applicant_name | Eli Lilly and Company |
| application_type | BLA |
| approval_date | 1996-06-14 |
Revenue by product
HUMALOG
| Period | Revenue |
|---|---|
| Q4 2024 | $619.9M |
| Q3 2024 | $534.6M |
| Q2 2024 | $631.6M |
| Q1 2024 | $538.7M |
| Q4 2023 | $366.6M |
| Q3 2023 | $395.4M |
| Q2 2023 | $440.4M |
| Q1 2023 | $460.9M |
| Q4 2022 | $548.3M |
| Q3 2022 | $447.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
HUMALOG PEN
| Period | Revenue |
|---|---|
| Q4 2024 | $619.9M |
| Q3 2024 | $534.6M |
| Q2 2024 | $631.6M |
| Q1 2024 | $538.7M |
| Q4 2023 | $366.6M |
| Q3 2023 | $395.4M |
| Q2 2023 | $440.4M |
| Q1 2023 | $460.9M |
| Q4 2022 | $548.3M |
| Q3 2022 | $447.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
HUMALOG
| Period | Revenue |
|---|---|
| Q4 2024 | $619.9M |
| Q3 2024 | $534.6M |
| Q2 2024 | $631.6M |
| Q1 2024 | $538.7M |
| Q4 2023 | $366.6M |
| Q3 2023 | $395.4M |
| Q2 2023 | $440.4M |
| Q1 2023 | $460.9M |
| Q4 2022 | $548.3M |
| Q3 2022 | $447.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (6)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| HUMALOG | INSULIN LISPRO RECOMBINANT | 1,000UNITS/10ML (100UNITS/ML) | Injection |
| HUMALOG | INSULIN LISPRO RECOMBINANT | 300UNITS/3ML (100UNITS/ML) | Injection |
| HUMALOG | INSULIN LISPRO RECOMBINANT | 300UNITS/3ML (100UNITS/ML) | Injection |
| HUMALOG | INSULIN LISPRO RECOMBINANT | 300UNITS/3ML (100UNITS/ML) | Injection |
| HUMALOG | INSULIN LISPRO RECOMBINANT | 300UNITS/3ML (100UNITS/ML) | Injection |
| HUMALOG | — | 300UNITS/3ML (100UNITS/ML) | Injection |
6 products